PHARMA SOLUTIONS

Smarter imaging solutions for faster clinical trials

We offer proprietary biomarkers focused on the identification and monitoring of disease in clinical trials, delivered as a turn-key medical imaging solution via a secure, cloud-based software as a service (SaaS).

Our Focus Areas

Cardiometabolic

Multi-organ services delivered through quantitative MRI and DXA to support obesity, metabolic, and neuromuscular disease-focused clinical trials.

MASLD/MASH & Cirrhosis

Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.

Autoimmune Disease

Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.

Gastrointestinal Disease

Rapid, high-quality sample processing with a fully digitized reporting workflow and quantitative AI-pathology.

Oncology Solutions

Integrated analysis of our noninvasive, multi-organ & tumor characterization software, digital pathology, and endoscopy, enables a deeper rapid analysis of the patient and their cancer.

1200+

Locations Worldwide

100+

Research Partners

90+

Papers Published

75+

Interventional Trials

40,000+

Trial Datasets Processed

Case Studies

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Rohit Loomba, M.D. https://orcid.org/0000-0002-4845-9991, Mark L. Hartman, M.D., Eric J. Lawitz, M.D., Raj Vuppalanchi, M.D., Jérôme Boursier, M.D., Ph.D., Elisabetta Bugianesi, M.D., Ph.D., Masato Yoneda, M.D., Ph.D., Cynthia Behling, M.D., Ph.D., Oscar W. Cummings, M.D., Yuanyuan Tang, Ph.D., Bram Brouwers, Ph.D., Deborah A. Robins, M.S., Amir Nikooie, Ph.D., Mathijs C. Bunck, M.D., Ph.D., Axel Haupt, M.D., Ph.D., and Arun J. Sanyal, M.D., for the SYNERGY-NASH Investigators^*

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Rohit Loomba, M.D., M.H.Sc. https://orcid.org/0000-0002-4845-9991, Arun J. Sanyal, M.D., Kris V. Kowdley, M.D., Deepak L. Bhatt, M.D., M.P.H., Naim Alkhouri, M.D. https://orcid.org/0000-0001-9872-2391, Juan P. Frias, M.D. https://orcid.org/0000-0001-9486-1255, Pierre Bedossa, M.D., Ph.D., Stephen A. Harrison, M.D., Donald Lazas, M.D., Robert Barish, M.D., Mildred D. Gottwald, Pharm.D., Shibao Feng, Ph.D., Germaine D. Agollah, Ph.D., Cynthia L. Hartsfield, Ph.D., Hank Mansbach, M.D., Maya Margalit, M.D., and Manal F. Abdelmalek, M.D., M.P.H.

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

Stephen A. Harrison, Sarah K. Browne,John J. Suschak,Shaheen Tomah, Julio A. Gutierrez, Jay Yang, M. Scot Roberts, M. Scott Harris

AWS Health Innovation Podcast

In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, Principal Healthcare and Life Sciences Startups Business Development Manager at Amazon Web Services, sits down with Rajarshi Banerjee, aka ‘Banjo’, the CEO of, a company revolutionizing the way we diagnose and monitor chronic diseases.

Listen on Healthpodcastnetwork.com